1-甲基-1H-吲哚-5-胺 | 102308-97-4

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 1-甲基-1H-吲哚-5-胺
• 中文别名: N-甲基-5-氨基吲哚；1-甲基吲哚-5-胺；1-甲基-5-氨基吲哚；5-氨基-1N-甲基吲哚
• 英文名称: 1-methyl-1H-indol-5-amine
• 英文别名: 1-methyl-5-aminoindole；5-amino-1-methylindole；1-methyl-5-amino-1H-indole；1-methyl-1H-indole-5-amine；5-amino-1-methyl-1H-indole；5-amino-1-N-methylindole；1-methylindol-5-amine
• CAS: 102308-97-4
• 化学式: C₉H₁₀N₂
• 分子量: 146.192
• InChiKey: PGTSGPCXPIFQEL-UHFFFAOYSA-N

物化性质

• 熔点：
  102 °C
• 沸点：
  143-144 °C(Press: 2 Torr)
• 密度：
  1.15±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于乙腈（少许）、氯仿（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  31
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xn
• 安全说明：
  S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Amino-1-n-methylindole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H319: Causes serious eye irritation
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Amino-1-n-methylindole
CAS number: 102308-97-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H10N2
Molecular weight: 146.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

以1-甲基-1H-吲哚-5-氯为起始物料，经氨解反应制备得到1-甲基-1H-吲哚-5-胺；而以1-甲基-1H-吲哚-5-硝基为起始物料，则通过加氢还原反应（使用雷尼镍作为催化剂）同样可以制得1-甲基-1H-吲哚-5-胺。本文采用另一种方法，以5-硝基吲哚为起始物料，首先与碘甲烷反应生成1-甲基-1H-吲哚-5-硝基，再通过硝基还原最终得到目标化合物1-甲基-1H-吲哚-5-胺。其合成反应式如下图所示：

反应信息

• 作为反应物：
  描述：

  1-甲基-1H-吲哚-5-胺 在 吡啶 、 manganese(IV) oxide 、 氨 、 水 、 戴斯-马丁氧化剂 、 三乙胺 、 三氯氧磷 作用下， 以 四氢呋喃 、 二氯甲烷 、 苯 为溶剂， 反应 79.0h， 生成 BE-10988
  参考文献：
  名称：

  有机合成中的碘 (V) 试剂。第 2 部分。通过 Dess-Martin Periodinane-Generatedo-Imidoquinones 获得复杂的分子结构

  摘要：

  邻亚胺醌是一类相当罕见的化合物，它是由苯胺通过戴斯-马丁高碘烷 (DMP) 和水的作用制备的。它们的化学性质已被广泛研究并发现可产生对醌和不同分子结构的多环系统。描述了这种方法在天然化合物、环氧喹霉素 B 和 BE-10988 的全合成中的应用。最后，另一种罕见的化学实体，酮羟基酰胺部分，已通过这种基于 DMP 的合成技术获得，并对其反应性进行了研究。其最有用的反应之一是一组级联杂环环化，导致各种可能具有生物学相关性的多环系统。

  DOI：

  10.1021/ja012125p
• 作为产物：
  描述：

  N-(1-甲基吲哚-5-基)邻苯二甲酰亚胺 在 乙醇 、 一水合肼 作用下， 生成 1-甲基-1H-吲哚-5-胺
  参考文献：
  名称：

  Terent'ew; Preobrashenskaja, Zhurnal Obshchei Khimii, 1959, vol. 29, p. 317,322; engl. Ausg. S. 322, 326

  摘要：

  DOI：

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• Chemoselective transfer hydrogenation of nitroarenes by highly dispersed Ni-Co BMNPs
  作者：Jia-wei Zhang、Guo-ping Lu、Chun Cai

  DOI：10.1016/j.catcom.2016.05.023

  日期：2016.9

  Highly dispread Ni-Co bimetallic nanoparticles (Ni-Co BMNPs) are synthesized and applied as an efficient catalyst in the chemoselective transfer hydrogenation of nitroarenes (CTH) using hydrazine hydrate as the hydrogen donor. The BMNPs can efficiently catalyze the reduction reaction without any additives under mild conditions with high TOF. Significantly higher activity is achieved when compared with

  合成了高度分散的Ni-Co双金属纳米颗粒（Ni-Co BMNPs），并使用水合肼作为氢供体，将其作为有效的催化剂用于硝基芳烃（CTH）的化学选择性转移加氢。在高TOF的温和条件下，无需任何添加剂，BMNP即可有效催化还原反应。与相应的单组分催化剂相比，可以显着提高活性，筛选出Ni-Co BMNPs的最佳组成，事实证明这对选择性和收率都至关重要。Ni-Co BMNP的出色性能归因于BMNPs表面活性位点的改善分散性（与Ni NPs相比）以及电子从钴到镍的转移。
• Cyclic (Alkyl)(amino)carbene Ligand-Promoted Nitro Deoxygenative Hydroboration with Chromium Catalysis: Scope, Mechanism, and Applications
  作者：Lixing Zhao、Chenyang Hu、Xuefeng Cong、Gongda Deng、Liu Leo Liu、Meiming Luo、Xiaoming Zeng

  DOI：10.1021/jacs.0c12318

  日期：2021.1.27

  Transition metal catalysis that utilizes N-heterocyclic carbenes as noninnocent ligands in promoting transformations has not been well studied. We report here a cyclic (alkyl)(amino)carbene (CAAC) ligand-promoted nitro deoxygenative hydroboration with cost-effective chromium catalysis. Using 1 mol % of CAAC-Cr precatalyst, the addition of HBpin to nitro scaffolds leads to deoxygenation, allowing for

  利用 N-杂环卡宾作为非无害配体促进转化的过渡金属催化尚未得到很好的研究。我们在这里报告了具有成本效益的铬催化的环状（烷基）（氨基）卡宾（CAAC）配体促进的硝基脱氧硼氢化反应。使用 1 mol % 的 CAAC-Cr 预催化剂，将 HBpin 添加到硝基支架上会导致脱氧，从而保留各种可还原的官能团和敏感基团对硼氢化的相容性，从而提供一种温和、化学选择性和易于形成的策略苯胺，以及杂芳基和脂肪胺衍生物，具有广泛的范围和特别高的转换数（高达 1.8 × 106）。基于理论计算的机械研究，表明CAAC配体在促进HBpin氢化物极性反转中起重要作用；它用作 H 穿梭以促进脱氧硼氢化。通过这种策略制备的几种市售药物突出了其在药物化学中的潜在应用。
• HTS-based discovery and optimization of novel positive allosteric modulators of the α7 nicotinic acetylcholine receptor
  作者：István Ledneczki、Anita Horváth、Pál Tapolcsányi、János Éles、Katalin Dudás Molnár、István Vágó、András Visegrády、László Kiss、Áron Szigetvári、János Kóti、Balázs Krámos、Sándor Mahó、Patrik Holm、Sándor Kolok、László Fodor、Márta Thán、Diána Kostyalik、Ottilia Balázs、Mónika Vastag、István Greiner、György Lévay、Balázs Lendvai、Zsolt Némethy

  DOI：10.1016/j.ejmech.2021.113560

  日期：2021.10

  HTS campaign of the corporate compound collection resulted in a novel, oxalic acid diamide scaffold of α7 nACh receptor positive allosteric modulators. During the hit expansion, several derivatives, such as 4, 11, 17 demonstrated not only high in vitro potency, but also in vivo efficacy in the mouse place recognition test. The advanced hit molecule 11 was further optimized by the elimination of the

  公司化合物收集的 HTS 活动产生了一种新型的 α7 nACh 受体阳性变构调节剂草酸二酰胺支架。在命中膨胀，几个衍生物，如4，11，17证明不仅高体外效力，而且在体内在小鼠地方识别测试功效。先进的命中分子11通过消除推定的诱变芳香胺结构单元而得到进一步优化，该结构单元产生了一个新的氨基甲基吲哚化合物家族。在化合物55 的情况下发现了最平衡的物理化学和药理学特征。对接研究揭示了一个亚基间结合位点是我们的化合物最可能的。55不仅在东莨菪碱诱导的健忘症（小鼠位置识别测试）中，而且在自然遗忘（大鼠新物体识别测试）中表现出良好的认知增强特征。此外，化合物55在具有高转化价值的认知范式中是活跃的，即在大鼠触摸屏视觉辨别测试中。因此，选择55作为先导化合物进行进一步优化。基于获得的有利结果，本发明的氨基甲基吲哚簇可以通过α7 nAChR的正变构调节为认知增强提供可行的方法。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。